As of 2026-08-14, the Fair Value of Denali Therapeutics Inc (DNLI) is -16.15 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 24.82 USD, the upside of Denali Therapeutics Inc is -165.06%.
With the market price of 24.82 USD and our fair value calculation, Denali Therapeutics Inc (DNLI) is not a good investment. Investing in DNLI stocks now will result in a potential loss of 165.06%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | 5Y Avg | |
| Net income | -290.60 | -326.00 | -145.22 | -422.77 | -512.54 | -339.43 |
| YoY growth | -508.72% | -12.18% | 55.45% | -191.12% | -21.23% | -135.56% |
| Market Cap (mil) | 3,939.18 |
| P/E | |
| Forward P/E |
| EPS | -3.23 |
| Avg earnings growth rate | -135.56% |
| TTM earnings | -512.54 |